BMC NephrologyPub Date : 2025-08-18DOI: 10.1186/s12882-025-04396-6
I Trutin, L Oletić, D Galešić Ljubanović, D Krgović, Tamara Nikuševa Martić
{"title":"How does LAMB2 contribute to kidney disease? Insights from a pediatric case.","authors":"I Trutin, L Oletić, D Galešić Ljubanović, D Krgović, Tamara Nikuševa Martić","doi":"10.1186/s12882-025-04396-6","DOIUrl":"10.1186/s12882-025-04396-6","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"465"},"PeriodicalIF":2.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-18DOI: 10.1186/s12882-025-04399-3
Amira Reda Muhammad Galal, Nahla Mohamed Teama, Karema Abu-Elfotuha, Ahmed D Alatawi, Hanan Alshareef, Ahmed M E Hamdan, Ahmed Aljabri, Mohannad Alshibani, Zeinab AlKasaby Mahmoud Zalat
{"title":"The potential adding therapeutic effect of pentoxifylline and/or folic acid for chronic kidney disease patients: randomized controlled trial.","authors":"Amira Reda Muhammad Galal, Nahla Mohamed Teama, Karema Abu-Elfotuha, Ahmed D Alatawi, Hanan Alshareef, Ahmed M E Hamdan, Ahmed Aljabri, Mohannad Alshibani, Zeinab AlKasaby Mahmoud Zalat","doi":"10.1186/s12882-025-04399-3","DOIUrl":"10.1186/s12882-025-04399-3","url":null,"abstract":"<p><strong>Background/objectives: </strong>Chronic kidney disease (CKD) is a highly prevalent, irreversible, and progressive disease associated with a high cardiovascular risk. We aimed to clinically investigate the extra-therapeutic effect of adding therapeutic doses of pentoxifylline (PTX) and/or folic acid (FA) for CKD patients to the standard care on their health-related quality.</p><p><strong>Methods: </strong>A randomized, prospective, parallel, and controlled clinical trial of CONSORT 80 patients diagnosed with CKD stages 3-5 were stratified by simple randomization into four groups (20 patient/group) and followed up for 6 months.</p><p><strong>Control group: </strong>received standard usual care therapy only; PTX group: received therapeutic dose of PTX added to standard usual care therapy; FA group: received FA added to standard usual care therapy; and PTX and FA group: received both PTX and FA added to their standard usual care therapy. The primary objective was to compare the renal function biochemical parameters for the intervention groups compared to the control group. Meanwhile, the secondary objective was to compare the incidence of readmission to hospitalization with cardiovascular events, incidence of peripheral vascular diseases and Fatigue Assessment Scale (FAS) for the intervention groups compared to the control group.</p><p><strong>Clinical trial registration: </strong>This study's research was granted authorization by the Research Ethics Committee (REC), Faculty of Medicine, Ain Shams University, No. (FMASU MS UNIV 15/2022) dated to 15/12/2022, and the Ethical Committee in the Faculty of Pharmacy (Girls), Al-Azhar University, No. (313) dated to 22/12/2022. This study was authorized by https://clinicaltrials.gov/ (NCT05284656) and the first date of registration was 16/02/2022. All patients were assigned to write an informed consent.</p><p><strong>Results: </strong>There was a significant improvement in renal function biochemical parameters and a significant reduction in the FAS for the intervention groups compared to the control group.</p><p><strong>Conclusions: </strong>Our results demonstrated that administration of therapeutic doses of PTX and/or FA in CKD patients delayed the progression of advanced chronic kidney disease and has been used successfully improved their health-related quality of life.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"468"},"PeriodicalIF":2.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-14DOI: 10.1186/s12882-025-04374-y
Emma Aitken, Hameed Anijeet, Damien Ashby, Wayne Barrow, Francis Calder, Brett Dowds, Catherine Fielding, James Gilbert, Rob Jones, Narayan Karunanithy, Zaib Khawaja, Emma Roberts, Mike Robson, Rukshana Shroff, Hannah Stacey, Peter Thomson, Dan Waters
{"title":"UK Kidney Association Clinical Practice Guideline on vascular access for haemodialysis.","authors":"Emma Aitken, Hameed Anijeet, Damien Ashby, Wayne Barrow, Francis Calder, Brett Dowds, Catherine Fielding, James Gilbert, Rob Jones, Narayan Karunanithy, Zaib Khawaja, Emma Roberts, Mike Robson, Rukshana Shroff, Hannah Stacey, Peter Thomson, Dan Waters","doi":"10.1186/s12882-025-04374-y","DOIUrl":"10.1186/s12882-025-04374-y","url":null,"abstract":"<p><p>This guideline is written primarily for doctors and nurses working in dialysis centres and related areas of medicine in the UK, and is an update of a previous version written in 2015. It aims to provide guidance on how to provide vascular access care for patients approaching and undergoing haemodialysis, and provides a standard of care which centres should in general aim to achieve. We would not advise patients to interpret the guideline as a rulebook, but perhaps to answer the question: \"What does good quality vascular access care look like?\". The guideline is split into sections: each begins with a few statements which are graded by strength (1 is a firm recommendation, 2 is more like a sensible suggestion), and the type of research available to back up the statement, ranging from A (good quality trials so we are pretty sure this is right) to D (more like the opinion of experts than known for sure). After the statements there is a short summary explaining why we think this, often including a discussion of some of the most helpful research. There is then a list of the most important medical articles so that you can read further if you want to - most of this is freely available online, at least in summary form. A few notes on the individual sections: 1. This section covers key concepts relevant to vascular access and focusses on access type selection, including a historical introduction and review of the key literature informing our understanding. This explains why we are moving away from the outdated advice in previous guidelines (e.g. that 'all patients should dialyse with a fistula as first choice') towards a process which treats dialysis access selection as a choice, respecting patient individuality, aiming to provide high quality assessment and advice, so that patients are supported in making informed decisions. The basic concept of the fistula as optimal access is highlighted and remains valid, but it is placed within a more modern concept of care, in which the patient is at the centre of the decision process. 2. This section addresses the initial planning of access, from education and vein preservation, through to the timing of assessment and access formation, emphasising in particular the need to plan ahead. 3. This section deals with the formation and routine care of AV access (fistulas and grafts), covering access type and configuration, surgical and anaesthetic technique, the maturation period (before a fistula is ready to be used), and initiation and maintenance of optimal cannulation (needling). 4. This section deals with some of the complications of AV access. Research in this area is ongoing and not yet sufficient to give clear guidance, so we emphasise again the importance of involving patients in treatment decisions. 5. This section deals with the placement and routine care of catheter access (lines), covering location, technique, anticoagulant locks, and regular exit site disinfection and dressings. 6. This section d","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"461"},"PeriodicalIF":2.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-14DOI: 10.1186/s12882-025-04394-8
Maria Qadri, Shafiq Ur Rahman, Hammad Javaid, Kritick Bhandari, Rahman Syed, Ameer Afzal Khan, Zaryab Bacha, Rizwana Noor, Maryem Filal
{"title":"Trends in chronic kidney disease mortality among patients with systemic lupus erythematosus: a U.S. population-based study (1999-2020).","authors":"Maria Qadri, Shafiq Ur Rahman, Hammad Javaid, Kritick Bhandari, Rahman Syed, Ameer Afzal Khan, Zaryab Bacha, Rizwana Noor, Maryem Filal","doi":"10.1186/s12882-025-04394-8","DOIUrl":"10.1186/s12882-025-04394-8","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"462"},"PeriodicalIF":2.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-13DOI: 10.1186/s12882-025-04365-z
David J Tunnicliffe, Ieuan Wickham, Allison Jauré, Brydee Johnston, Andrew J Mallett, Adam Mullan, Lyn Lloyd, Nicole Scholes-Roberston, Hicham Cheikh Hassan, Matthew Jose
{"title":"Correction: Identifying and integrating consumer-prioritised topics and outcomes in clinical practice guidelines on managing kidney stones.","authors":"David J Tunnicliffe, Ieuan Wickham, Allison Jauré, Brydee Johnston, Andrew J Mallett, Adam Mullan, Lyn Lloyd, Nicole Scholes-Roberston, Hicham Cheikh Hassan, Matthew Jose","doi":"10.1186/s12882-025-04365-z","DOIUrl":"10.1186/s12882-025-04365-z","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"456"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-13DOI: 10.1186/s12882-025-04375-x
Mutlaq Alotaibi, Najlaa Almalki, Manal E Alotaibi, Majed Alosaimi, Monther Alazwari, Mohamed Hussein, Faisal Alhomayani, Abdulmajeed Alotaibi, Ameerah Bajaber, Fahad Bhutto, Abdulmajeed Algethami, Bassem A Almalki
{"title":"Incidence and risk factors of post-transplant diabetes mellitus among kidney transplant recipients: a retrospective study from a tertiary center in Saudi Arabia.","authors":"Mutlaq Alotaibi, Najlaa Almalki, Manal E Alotaibi, Majed Alosaimi, Monther Alazwari, Mohamed Hussein, Faisal Alhomayani, Abdulmajeed Alotaibi, Ameerah Bajaber, Fahad Bhutto, Abdulmajeed Algethami, Bassem A Almalki","doi":"10.1186/s12882-025-04375-x","DOIUrl":"10.1186/s12882-025-04375-x","url":null,"abstract":"","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"460"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-13DOI: 10.1186/s12882-025-04393-9
Amirali Ahrabi, Sepideh Poshtdar, Javad Salimi, Mohammad Ashouri, Mehdi Yaseri
{"title":"Patient perspective and satisfaction with different types of vascular access in hemodialysis: a systematic review and meta-analysis.","authors":"Amirali Ahrabi, Sepideh Poshtdar, Javad Salimi, Mohammad Ashouri, Mehdi Yaseri","doi":"10.1186/s12882-025-04393-9","DOIUrl":"10.1186/s12882-025-04393-9","url":null,"abstract":"<p><strong>Background: </strong>To assess satisfaction and perspectives of adult hemodialysis (HD) patients on different vascular access (VA) types (AVF, AVG, CVC) by synthesizing quantitative studies using validated questionnaires, focusing on overall satisfaction, physical symptoms, social functioning, and complications.</p><p><strong>Methods: </strong>We systematically searched Medline, Web of Science, and Scopus for studies assessing adult HD patients' perspectives on VA using structured questionnaires. Risk of bias was assessed using the Newcastle-Ottawa Scale. Meta-analysis was performed using a random-effects model across three pairwise comparisons: AVF vs. CVC, AVF vs. AVG, and CVC vs. AVG.</p><p><strong>Results: </strong>Of 1,253 records, 11 studies (n = 2910) met inclusion criteria. AVF patients had higher overall satisfaction compared to those with CVCs (MD: 7.06%, 95% CI: 2.98-11.14). Compared to AVG, AVF patients had higher overall satisfaction, though not statistically significant (MD: 5.12%, 95% CI: - 0.42 to 10.66; p = 0.069). Dissatisfaction with physical symptoms was significantly higher in AVF patients than in those with CVCs (MD: 8.76%, 95% CI: 4.19 to 13.34). Compared to CVC, AVF patients reported significantly lower dissatisfaction in both social functioning (MD: - 9.48%, 95% CI: - 15.98 to - 2.98) and dialysis-related complications (MD: - 10.08%, 95% CI: -12.66 to -7.50).</p><p><strong>Conclusions: </strong>AVFs are associated with higher overall patient satisfaction compared to other VA types. While AVF patients experience more physical discomfort, this is outweighed by significantly greater satisfaction in areas such as social functioning and dialysis-related complications. These findings emphasize the importance of considering patient-reported outcomes when evaluating VA options in HD care.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"457"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-13DOI: 10.1186/s12882-024-03916-0
Ye Cheng, Pei Liu, Guiling Xie, Wenjun Li, Huan Jing, Yanna Chen, Hongtao Chen, Youlin Fan, Jun Zhou
{"title":"DNA methylation in chronic kidney disease.","authors":"Ye Cheng, Pei Liu, Guiling Xie, Wenjun Li, Huan Jing, Yanna Chen, Hongtao Chen, Youlin Fan, Jun Zhou","doi":"10.1186/s12882-024-03916-0","DOIUrl":"10.1186/s12882-024-03916-0","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a condition that affects people on a global scale. After various stages of progression, CKD is finally characterized by renal fibrosis. As the most pervasive and well-studied epigenetic modification, DNA methylation has recently been associated with the development of renal fibrosis. Gaining a better understanding of the link between DNA methylation and CKD would provide new targets or enable the development of epigenetic therapies for CKD. This review discusses the mechanisms by which DNA methylation regulates gene expression during the pathological process of CKD, including the role of DNA methyltransferases (DNMTs). This review summarizes DNA methylation in CKD, particularly its crucial role in CKD-related conditions, such as diabetic kidney disease (DKD) and chronic allograft injury. Conventional demethylating agents have been discussed as well as the need for less toxic demethylating agents for clinical applications. Finally, some of the problems and obstacles specified in previous DNA methylation studies have been considered. This information aims to promote further investigations into the role of DNA methylation in CKD by providing novel insights into the mechanism by which methylation affects the progression and regression of CKD, which would result in the development of alternate treatments.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"455"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC NephrologyPub Date : 2025-08-13DOI: 10.1186/s12882-025-04378-8
Christian Goul Sørensen, Simon Kok Jensen, Reimar Wernich Thomsen, Bente Jespersen, Sigrid Bjerge Gribsholt, Christian Fynbo Christiansen
{"title":"Kidney outcomes after bariatric surgery: a population-based cohort study.","authors":"Christian Goul Sørensen, Simon Kok Jensen, Reimar Wernich Thomsen, Bente Jespersen, Sigrid Bjerge Gribsholt, Christian Fynbo Christiansen","doi":"10.1186/s12882-025-04378-8","DOIUrl":"10.1186/s12882-025-04378-8","url":null,"abstract":"<p><strong>Background: </strong>Bariatric surgery may mitigate obesity-related chronic kidney disease (CKD) but may concurrently increase the risk of acute kidney injury (AKI) and hyperoxaluria. We examined kidney outcomes after bariatric surgery.</p><p><strong>Methods: </strong>Using population-based registries, we included individuals with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) in Denmark between 2006 and 2018. These were age- and sex-matched 1:5 to individuals with hospital-diagnosed overweight/obesity without bariatric surgery. Cumulative incidences (risks) of AKI, nephrolithiasis, CKD (stage G3-G5), and kidney failure with replacement therapy (KFRT) were computed, accounting for the competing risk of death. Cox regression was used to estimate hazard ratios (HR) adjusted for age, sex, and comorbidity.</p><p><strong>Results: </strong>We included 18,827 individuals with bariatric surgery (17,200 RYGB and 1,627 SG) and 94,135 individuals in the matched overweight/obesity cohort (median age 41 years, median follow-up 8.1 years). The one-year risk of AKI following bariatric surgery was 2.7%, while the ten-year risks of nephrolithiasis, CKD, and KFRT were 3.5%, 0.4%, and 0.2%, respectively. When comparing individuals with bariatric surgery with those with overweight/obesity, the adjusted HRs were increased at 1.63 (95% CI; 1.38, 1.92) for AKI and 1.73 (95% CI; 1.56, 1.91) for nephrolithiasis. In contrast, adjusted HRs were decreased at 0.41 (95% CI; 0.26, 0.66) for CKD and 0.63 (95% CI; 0.42, 0.95) for KFRT. Similar results were observed versus a population comparison cohort.</p><p><strong>Conclusions: </strong>Bariatric surgery was associated with an increased risk of AKI and nephrolithiasis, while long-term risks of CKD and KFRT were lower than in matched individuals with overweight/obesity.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":"26 1","pages":"458"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}